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Supplementary Figure 1. Gating scheme for single B cell sorting. Gating scheme for isolation 
of antigen-specific memory B cells (CD19+, CD27+, IgM-, JUNV GP1+). Asterisk indicates the 
exclusion channel; in Sort 2 (Fig. 1c), the exclusion channel also included cells that stained 
positive for JUNV GP1mut-PerCP. 
 
 
 
 
 
 
  
Supplementary Figure 2. Analysis of CR1-06 and CR1-09 binding to JUNV GP1. (a) ELISA 
of CR1-06 IgG binding to immobilized JUNV GP1. LUJV GP1 is a control. Error bars, which 
indicate standard deviation, are smaller than symbols. (b) Sensorgrams for binding of CR1-09 
Fab to immobilized JUNV GP1 as measured by surface plasmon resonance. CR1-09 Fab was 
passed over the surface at concentrations of 400 nM, 200 nM, 100 nM, 50 nM, and 25 nM. The 
recorded sensorgrams (one of duplicates) are shown. The fast off rate prevented accurate fitting 
of the data to estimate binding kinetics. 
 
 
Supplementary Figure 3. CR1-07 and CR1-28 compete with GD01 for binding to JUNV GP1. 
Competitor IgG (GD01 or 17b) was added at increasing concentrations to plates coated with 
JUNV GP1. After an incubation step, CR1-10 IgG (left panel), CR1-07 IgG (middle panel), or CR1-
28 IgG (right panel) were added at fixed concentrations. After several wash steps, CR1-07, CR1-
10, or CR1-28 IgG that bound to the plate was detected using an anti-human IgG secondary 
antibody. The experiment was performed twice in duplicate and representative data are shown. 
Error bars indicate standard deviation (S.D.). 
 
 
Supplementary Figure 4. Electron density for the CR1-10 Fab/JUNV GP1/CR1-28 Fab 
complex. (a) Part of the CR1-10 Fab/JUNV GP1 interface is shown as sticks with the refined 2Fo-
Fc electron density at 1 σ. (b) Part of the CR1-28 Fab/JUNV GP1 interface is shown as sticks with 
the refined 2Fo-Fc electron density at 1 σ. (c) 2Fo-Fc electron density at 1 σ for a N-linked glycan 
(shown as green sticks) attached at JUNV GP1 Asn178. 
 
 
 
 
 
 
 Supplemental Figure 5. CR1-10 binds cell-surface expressed JUNV GPC trimer. We 
transfected HEK293T cells with JUNV GPC and measured binding of CR1-28 IgG, CR1-10 IgG, 
or 17b IgG (control) by FACS 48 hr after transfection. Mean fluorescence intensity (MFI) values 
for antibody-binding to transfected cells were corrected by subtraction of MFI obtained at the 
same antibody concentration with control, untransfected HEK293T cells. The EC50 for CR1-28 
and CR1-10 binding to cells transfected with JUNV GPC was measured as 0.32 µg ml-1 and 1.9 
µg ml-1, respectively. Error bars indicate S.D. For some data points, error bars are smaller than 
symbols. The experiment was performed twice in duplicate and representative data are shown. 
 Supplementary Figure 6. CR1-07 Fab structure and electron density for MACV GP1/CR1-07 
Fab complex. (a) Ribbon diagram of the unliganded CR1-07 Fab (heavy chain in gray, light chain 
in black). HC: heavy chain; LC: light chain. (b) Part of the MACV GP1/CR1-07 Fab interface is 
shown as sticks with the refined 2Fo-Fc electron density at 1 σ. (c) One of the four Fab copies 
(representative) found in the asymmetric unit of the MACV GP1/CR1-07 Fab complex was 
overlaid onto the unliganded CR1-07 Fab. The tip CR1-07 CDR L1 shifts by about 6 Å to 
accommodate MACV GP1 in the complex. 
 
Supplementary Figure 7. CR1-07 contact residues in MACV GP1. (a) Ribbon diagram of 
MACV GP1 with residues that are contacted by CR1-07 shown as sticks and colored red. 
Asparagines that are potential sites of N-linked glycan attachment are shown as sticks and 
indicated with an asterisk. (b) List of CR1-07 contact residues in MACV GP1 and residues at the 
analogous positions in the GP1s of other New World arenaviruses (using MACV GP1 numbering). 
Residues highlighted in grey are identical between MACV and the indicated GP1.  
 
 Supplementary Figure 8. Model of neutralizing antibody binding to the pre-fusion 
arenavirus GPC ectodomain. (a) The MACV GP1/TfR1 complex (PDB: 3KAS)1 was overlaid 
onto the structure of the prefusion LASV GPC ectodomain (PDB: 5VK2)2 by aligning the GP1 
proteins, which have a similar fold. One of the three GP1:GP2 protomers is colored for GPC. (b) 
Left: Structure of the JUNV GP1/GD01 Fab complex (PDB: 5EN2)3 overlaid onto the prefusion 
LASV GPC ectodomain structure as in a. Right: Structure of the JUNV GP1/CR1-28 Fab 
subcomplex overlaid onto the LASV GPC ectodomain structure as in a. GD01 and CR1-28 are 
receptor-mimicking antibodies. (c) Structure of the MACV GP1/CR1-07 Fab complex overlaid onto 
the structure of the LASV GPC as in a. CR1-07 is a JUNV/MACV cross-neutralizing antibody. (d) 
The JUNV GP1/CR1-10 Fab complex was overlaid onto LASV GPC as in a, with two of the 
protomers in trimeric GPC shown as transparent to allow for better visualization of the binding 
site. CR1-10 is a non-neutralizing antibody. For all panels, the New World arenavirus GP1 protein 
used for structural alignment is omitted for clarity. 
 
 
Supplementary Figure 9. Sample electron density for the reported X-ray crystal structures. 
(a) Sample electron density for the unliganded CR1-07 Fab crystal structure. The volume shown 
in stereoview is from the 2Fo-Fc electron density map contoured at 1.5 σ in the region 
corresponding to light chain residues 39-47. (b) Sample electron density for the CR1-10 
Fab/JUNV GP1/CR1-28 Fab crystal structure. The volume shown in stereoview is from the 2Fo-
Fc electron density map contoured at 1.0 σ in the region corresponding to residues 32-39 of the 
CR1-28 heavy chain (chain T in the asymmetric unit). (c) Sample electron density for the MACV 
GP1/CR1-07 Fab crystal structure. The volume shown in stereoview is from the 2Fo-Fc electron 
density map contoured at 1.0 σ in the region corresponding to CR1-07 Fab heavy chain residues 
32-39 (chain F in the asymmetric unit). 
 
Supplementary Table 1. Properties of GP1-directed antibodies.  
Antibody VH D JH CDR3 Length Mutations % Mutation 
CR1-06 3-7 3-10 4/5 AKVGGHSAFYKTGRVGFDS 19 39 13.4% 
CR1-07 3-30 3-16/3-9 4 AKDLSPPYSYAWDIFQY  17 39 13.2% 
CR1-09 4-4 2-15 4 ARYCSGSACVPFDF 14 27 9.2% 
CR1-10 4-31 2-15 4 ARLTSDCSGGNCYQAFDY 18 33 11.1% 
CR1-28 3-33 6-13 4 ATDKTYVSGYTSTWYYFNY 19 11 3.7% 
*GD01 1-4/1-7 1-1 4 ARRRVYYGSNYIYALDY 17 38 13.0% 
        
  Vk Jk CDR3 Length Mutations % Mutation  
CR1-06 1-12/1D-12 2 QQGNSLPYT 9 39 13.70%  
CR1-07 4-1 4 QQYYSSPPT 9 14 6.6%  
CR1-09 3-20 1 LQYGTRPRT 9 21 7.3%  
CR1-10 3-20 2 QQYGRSGYT 9 9 3.2%  
CR1-28 1-5 1 QHRT 4 4 1.5%  
*GD01 6-13 5 QQYSSYPLA 9 6 2.1%  
 
*For GD01, murine antibody gene usage patterns are shown. 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. Binding rate constants of surface plasmon resonance analysis of 
antibody Fabs binding to immobilized GP1.  
 
Analyte Ligand ka (1/Ms) kd (1/s) KD (M) 
CR1-07 Fab JUNV GP1 8.52E+03 7.34E-04 8.62E-08 
CR1-10 Fab JUNV GP1 8.10E+05 3.65E-05 4.50E-11 
CR1-28 Fab JUNV GP1 1.05E+05 5.54E-04 5.30E-09 
CR1-07 Fab MACV GP1 4.13E+04 6.76E-04 1.60E-08 
 
 
 
Supplementary Table 3. Data collection and refinement statistics. 
 
  CR1-07 Fab  
CR1-10 Fab/JUNV 
GP1/CR1-28 Fab  
MACV GP1/CR1-07 
Fab 
Data collection       
Space group  C2  P21  P42212 
Cell dimensions       
    a, b, c  89.8 137.4 78.7  154.8 132.2 167.4  206.9 206.9 238.23 
Resolution (Å)  2.00 (2.07-2.00)a  3.99 (4.23-3.99)  3.91 (4.15-3.91) 
Rmerge  0.12 (1.02)  0.72 (1.58)  0.32 (8.38) 
CC1/2  99.4 (64.6)  79.6 (46.5)  99.5 (21.5) 
Avg I/σI  9.57 (1.65)  2.34 (1.03)  7.72 (0.52) 
Completeness (%)  97.9 (96.7)  99.1 (97.6)  98.8 (96.8) 
Average redundancy  4.5 (4.6)  3.4 (3.4)  8.1 (8.1) 
       
Refinement       
Resolution (Å)  44.21-2.00  49.35-3.99  49.12-3.91 
No. reflections  32,718  57,194  46,614 
Rwork/Rfree  0.23/0.28  0.24/0.29  0.25/0.26 
Number of Atoms       
   Protein  3,378  30,971  18,299 
   Water  223  -  - 
R.m.s. deviations       
    Bond lengths (Å)  0.005  0.008  0.012 
    Bond angles (°)  0.646  1.15  1.33 
Avg B-factor (Å2)       
    Protein  47.8  69.0  33.5 
    Water  44.8  -  - 
One crystal was used to collect each data set.  
aValues in parentheses are for highest-resolution shell  
 
 
Supplementary Table 4. XSCALE4 output summary. 
 
Subset of intensity data with signal to noise >=-3.0 as function of resolution for JUNV GP1 complex 
 
Resolution 
limit 
Reflections 
Observed 
Reflections 
Unique 
Reflections 
Possible 
Completeness 
of data 
R-factor 
observed 
R-factor 
expected Compared I/SIGMA R-meas CC(1/2) 
11.68 7797 2333 2406 97.00% 13.40% 13.80% 7764 7.53 16.00% 98.8* 
8.38 13247 3931 3973 98.90% 16.60% 16.90% 13167 6.55 19.80% 98.2* 
6.87 17016 5072 5115 99.20% 45.50% 45.20% 16869 2.91 54.10% 90.4* 
5.97 19914 5866 5902 99.40% 79.60% 79.30% 19792 1.84 94.60% 73.2* 
5.34 23300 6838 6867 99.60% 83.30% 82.20% 23160 1.78 99.00% 72.4* 
4.88 25365 7432 7450 99.80% 73.80% 73.40% 25241 1.97 87.80% 77.0* 
4.52 27660 8086 8114 99.70% 81.30% 80.50% 27538 1.85 96.60% 73.9* 
4.23 29698 8680 8705 99.70% 102.20% 100.70% 29599 1.57 121.60% 64.4* 
3.99 30534 8957 9177 97.60% 158.60% 156.70% 30401 1.03 188.60% 46.5* 
Total 194531 57195 57709 99.10% 72.10% 71.40% 193531 2.34 85.70% 79.6* 
 
 
 
Subset of intensity data with signal to noise >=-3.0 as function of resolution for MACV GP1 complex 
 
Resolution 
limit 
Reflections 
Observed 
Reflections 
Unique 
Reflections 
Possible 
Completeness 
of data 
R-factor 
observed 
R-factor 
expected Compared I/SIGMA R-meas CC(1/2) 
11.45 14549 2013 2093 96.20% 2.90% 3.60% 14523 46.89 3.10% 99.9* 
8.21 24884 3299 3341 98.70% 4.70% 5.00% 24836 33.4 5.00% 99.9* 
6.73 33344 4196 4237 99.00% 17.20% 17.30% 33296 12.92 18.40% 99.3* 
5.84 39740 4909 4943 99.30% 42.70% 42.80% 39700 6.31 45.60% 95.7* 
5.24 44300 5425 5464 99.30% 65.20% 65.30% 44265 4.42 69.60% 92.2* 
4.78 50412 6149 6173 99.60% 87.10% 87.00% 50371 3.49 92.90% 88.1* 
4.43 53993 6554 6581 99.60% 153.20% 152.80% 53962 2.15 163.30% 75.1* 
4.15 57007 6911 6937 99.60% 262.50% 261.40% 56980 1.25 279.70% 49.5* 
3.91 59863 7376 7621 96.80% 838.00% 834.60% 59833 0.52 894.00% 21.5* 
total 378092 46832 47390 98.80% 32.90% 33.10% 377766 7.72 35.10% 99.5* 
 
Definitions 
Compared Number of reflections used for calculating R-factor 
I/SIGMA Mean of intensity/Sigma(I) of unique reflections (after merging symmetry-
related observations) 
Sigma(I) Standard deviation of reflection intensity I estimated from sample statistics 
R-meas Redundancy independent R-factor (intensities) 
CC(1/2) 
 
Anomal Corr 
Percentage of correlation between intensities from random half-datasets. 
Correlation significant at the 0.1% level is marked by an asterisk. 
Percentage of correlation between random half-sets of anomalous intensity 
differences. Correlation significant at the 0.1% level is marked. 
SigAno Mean anomalous difference in units of its estimated standard deviation 
(|F(+)-F(-)|/Sigma). F(+), F(-) are structure factor estimates obtained from 
the merged intensity observations in each parity class. 
Nano Number of unique reflections used to calculate Anomal_Corr & SigAno. At 
least two observations for each (+ and -) parity are required. 
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